News
The Food and Drug Administration (FDA) has approved Welireg ™ (belzutifan) for the treatment of adult and pediatric patients aged 12 years and older with locally advanced, unresectable ...
4 1. FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or ...
FDA approves Merck’s belzutifan for pheochromocytoma or paraganglioma The Food and Drug Administration approved belzutifan, or Welireg, marketed by Merck (MRK), for adult and pediatric patients ...
Sanofi expands its U.S. manufacturing with a $20 billion investment. The FDA approves Merck's cancer drug for rare adrenal ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for adult and pediatric patients 12 years and older with locally advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results